Connect with us

Spread & Containment

Best Consumer Staples Stocks to Invest In

In this article, we’ll go over my top four consumer staples stocks that are looking to benefit in the long-term. Let’s get started…
The post Best…

Published

on

Consumer staples stocks have been on a rollercoaster throughout the COVID-19 pandemic. However, they have the necessities that consumers are looking for. And during the height of the pandemic, many people were ordering their products online. This worked out well for some companies, and today, we’ll go over my top four consumer staples stocks that are looking to benefit from the new wave of COVID-19 fears. Let’s get started…

Top Consumer Staples Stocks List for 2022

No. 4 Hormel Foods (NYSE: HRL)

Hormel Foods is over 130 years old. It’s a Fortune 500 company manufacturing brand-name food and meat products on a global scale. Hormel is a master of innovation. It currently has 52 brands under its belt. With its stellar leadership and dedication to making good food available to everyone, it’s no wonder why Hormel is one of the largest and most successful food companies in the world.

Regarding Hormel’s earnings report, its volume of 1.2 billion lbs. is up 2%. The company reported net sales of $3.0 billion, up 24%. And organic net sales are up 13%. Its operating income of $320 million is up 19% compared to 10.9% last year. And cash flow from operations of $384 million is up 87%. According to Jim Snee, chairman of the board, president and CEO, he believes the company is “on track to deliver our sales and earnings guidance for the year. Our team achieved its fifth consecutive quarter of record net sales and grew operating income by double digits during the first quarter.”

He continued by saying “We expect the demand environment to remain favorable, pricing actions to combat inflationary pressures and continued growth.” The operating environment looks to remain volatile, however, Hormel’s supply chain is on track to continue to show improvement.

Analysts believe Hormel to be a solid investment option for the long-term. However, it is up to you to do due diligence and research the company to see if it’s the right investment for you. Now, let’s look at a few more consumer staples stocks to consider for your portfolio.

No. 3 Tyson Foods (NYSE: TSN)

Tyson Food has quite the history. It started during the Great Depression in 1931. John W. Tyson started delivering chickens to large markets in the Midwest. In 1972, the company changed its name to Tyson Foods. In addition to the new name, it also introduced a new look. Tyson Foods is a staple in the food industry. The company has done so much for its community and consumers. Starting in 2000, the company became partners with Share Our Strength. So far, they’ve donated over 100 million pounds of products to hunger and disaster relief in over 49 states. And in 2014, Tyson Foods acquired The Hillshire Brands Company resulting in annual sales of over $40 billion. The company has completed 13 acquisitions.

Analysts are recommending holding this stock due to its recent stable pricing levels. The stock is looking to be a good long-term investment, considering the rise in food products due to inflation. Regarding Q1 results, the stocks GAAP earnings per share (EPS) of $3.07 is up 140% from the previous year. And adjusted EPS is up 48% from last year. GAAP operating income is up 106% from last year and adjusted operating income is also up from the previous year at a 40% increase. Donnie King, President and CEO said the company is very pleased with these results and believes “our future is bright.” And, Q2 results were just as impressive.

This consumer staples stock is adjusting and improving due to continued changes and effects of the market and global economy. Inflationary pressures are continuing across the supply chain. However, King praises the company by saying “we are working to drive costs down by continuing to increase our efficiency, productivity and bringing more capacity on line.” Tyson Foods plans to win with excellence in execution.

No. 2 Walgreens Boots Alliance (Nasdaq: WBA)

Walgreens Boots Alliance is a healthcare pharmacy and retailer. It’s one of the largest drugstore chains in the U.S. WBA owns Walgreens and Boots in addition to many other pharmaceutical manufacturing and distribution companies. The retail leader was formed in 2014 after Walgreens bought the 55% stake in Alliance Boots that it didn’t previously own.

According to CEO, Rosalind Brewer, Q1 results exceeded their expectations and the company is making immense progress in building out Walgreens Health. Brewer continued on by saying “we are raising our guidance for the full year and increasing investments in our people. Looking ahead, we are well positioned for sustainable, long-term value creation.” Much of its recent success is due to WBA’s integral role in COVID-19 vaccines and testing. This consumer staples stock is also the largest pediatric vaccine provider in the pharmaceutical industry.

WBA’s Q2 results demonstrated high earnings growth. The stocks Q2 sales increased 3% from the previous year Adjusted operating income was up 35.9%. With the company’s continued execution of strong results and innovative strategies to push the retail giant further, it’s no wonder why it was recently named one of the world’s 50 most innovative companies by Fast Company’s. Additionally, it was listed on Times 100 Most Influential Companies list.

Top Consumer Staple Stocks No. 1 Nestlé (OTC: NSRGY)

Nestlé began as the Anglo-Swiss Condensed Milk Company in 1866. Brothers, Charles and George Page founded the company. Nestlé founder, Henri Nestlé, was in fierce competition with the condensed milk brothers. In 1902, Anglo-Swiss merged with Nestlé. Nestlé started selling chocolate in 1904, and the rest is history. What was a once a condensed milk company is now a global powerhouse with over 2,000 brands under its roof. The brand categories range from baby food and healthcare nutrition to coffee and chilled & frozen food.

Nestlé reported three-month sales for 2022. So far, the results for this year are looking positive. Organic growth went up 7.6% and total reported sales increased by 5.4% to $22.2 billion. Mark Schneider, CEO, released a statement saying that in spite of these challenging times, “we delivered strong organic sales growth. Cost inflation continues to increase sharply, which will require further mitigating actions over the coming year.” He continued on to say that the “team addressed these headwinds and advanced our long-term strategy and sustainability objectives with agility and determination.”

This consumer staples stock believes the best way to be successful for the long-term is by creating value for shareholders and society. Their focus on shared value is so important right now. And Nestlé is doing a great job of harnessing that success for the long-term.

Keep Reading This Article and Find Out the Top 2 Consumer Staples Stocks to Buy Now


Enter your email below to read the reveal the top two consumer staples stocks.
You’ll also be opted in to receive our free daily e-letter, Investment U, where you’ll find expert investment insight, analysis and stock picks for all the best investment opportunities.

You’ll also receive occasional special offers from Oxford Club and our affiliates. You can unsubscribe at any time. Privacy Policy | Newsletter FAQ

"); } else if (data['response'] == 'Already Active On List') { // email already exists in system send confirmation anyway $(".status").html("
The email address is already on this list. You may now read the rest of the article.
"); } revive.setCookie(listCode, true, 365); function dieGated(){ $(".gated-content").show(); $(".gated").remove(); } setTimeout(dieGated, 3500); }; // hide iframe before adding src iframe.setAttribute("style", "display:none"); // iframe src should be the leadgen link iframe.src = signupUrl; iframe.setAttribute("id", "hacking_iris"); document.body.appendChild(iframe); } else if (data['response'] == 'Undeliverable') { $(".status").html("
Email was processed, but got an undeliverable error. Please check the email address and try again.
"); } else if (data['response'] == 'SpamTrap') { // invalid email $(".status").html("
We could not process this email address. Please check the email address and try again.
"); } else { // uknown error $(".status").html("
An error has occurred, please try again.
"); } }); // portrait });

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Government

New Hampshire Governor Vetoes Ivermectin Bill

New Hampshire Governor Vetoes Ivermectin Bill

Authored by Alice Giordano via The Epoch Times (emphasis ours),

New Hampshire’s Republican…

Published

on

New Hampshire Governor Vetoes Ivermectin Bill

Authored by Alice Giordano via The Epoch Times (emphasis ours),

New Hampshire’s Republican Gov. Chris Sununu vetoed a bill that would have made Ivermectin available without a prescription.

Ivermectin tablets packaged for human use. (Natasha Holt/The Epoch Times)

The Republican governor vetoed the bill on June 24, the same day that the U.S. Supreme Court overturned Roe v. Wade. Some fellow Republicans questioned the timing.

It certainly seemed like a convenient way to bury a veto of a bill that won support from the vast majority of Republicans in New Hampshire,” JR Hoell, co-founder of the conservative watchdog group RebuildNH, told The Epoch Times.

Hoell is a former four-term House Republican planning to seek re-election after a four-year hiatus from the the New Hampshire legislature.

Earlier this year, the New Hampshire Department of Children Youth and Family (DCYF) tried to take custody of Hoell’s 13-year old son after a nurse reported him for giving human-grade ivermectin to the teen months earlier.

Several states have introduced bills to make human-grade ivermectin available without a prescription at a brick and mortar store. Currently, it can be ordered online from another country. In April, Tennessee became the the first state to sign such a measure into law. New Hampshire lawmakers were first to introduce the idea.

Both chambers of the state’s Republican controlled legislature approved the bill.

In his statement explaining the veto, Sununu noted that there are only four other controlled medications available without a prescription in New Hampshire and that each were only made available after “rigorous reviews and vetting to ensure” before being dispensed.

“Patients should always consult their doctor before taking medications so that they are fully aware of treatment options and potential unintended consequences of taking a medication that may limit other treatment options in the future,” Sununu said in his statement.

Sununu’s statement is very similar to testimony given by Paula Minnehan, senior vice president of state government regulations for the New Hampshire Hospital Association, at hearings on the bill.

Minnehan too placed emphasis on the review that went into the four prescription medications the state made available under a standing order. They include naloxone, the generic name for Narcan, which is used to counter opioid overdoses, hormone replacement therapy drugs, and a prescription-version of the morning after pill.

It also includes a collection of smoking cessation therapy drugs like Chantix, which has been linked to suicide, depression, and other neuropsychiatric conditions. Last year, Pfizer, the leading maker of the FDA-approved drug, conducted a voluntarily recall of Chantix. Narcan has also been linked to deaths caused by severe withdrawals that have led to acute respiratory distress.

Rep. Melissa Blasek, a Republican co-sponsor of the New Hampshire ivermectin bill, told The Epoch Times, that one could veto any drug-related bill under the pretense of overdose concerns.

The reality is you can overdose on Tylenol,” she said. “Ivermectin has one of the safest track records of any drug.”

The use of human-grade ivermectin became controversial when some doctors began promoting it for the treatment and prevention of COVID-19. Government agencies including the FDA and CDC issued warnings against its use while groups like Front Line COVID-19 Critical Care Alliance (FLCCC) heavily promoted it.

Some doctors were  disciplined for prescribing human-grade ivermectin for COVID-19 including a Maine doctor whose medical license was suspended by the state.

Read more here...

Tyler Durden Thu, 06/30/2022 - 20:30

Read More

Continue Reading

Spread & Containment

Aging-US | Time makes histone H3 modifications drift in mouse liver

BUFFALO, NY- June 30, 2022 – A new research paper was published in Aging (Aging-US) on the cover of Volume 14, Issue 12, entitled, “Time makes histone…

Published

on

BUFFALO, NY- June 30, 2022 – A new research paper was published in Aging (Aging-US) on the cover of Volume 14, Issue 12, entitled, “Time makes histone H3 modifications drift in mouse liver.”

Credit: Hillje et al.

BUFFALO, NY- June 30, 2022 – A new research paper was published in Aging (Aging-US) on the cover of Volume 14, Issue 12, entitled, “Time makes histone H3 modifications drift in mouse liver.”

Aging is known to involve epigenetic histone modifications, which are associated with transcriptional changes, occurring throughout the entire lifespan of an individual.

“So far, no study discloses any drift of histone marks in mammals which is time-dependent or influenced by pro-longevity caloric restriction treatment.”

To detect the epigenetic drift of time passing, researchers—from Istituto di Ricovero e Cura a Carattere Scientifico, University of Urbino ‘Carlo Bo’, University of Milan, and University of Padua—determined the genome-wide distributions of mono- and tri-methylated lysine 4 and acetylated and tri-methylated lysine 27 of histone H3 in the livers of healthy 3, 6 and 12 months old C57BL/6 mice. 

“In this study, we used chromatin immunoprecipitation sequencing technology to acquire 108 high-resolution profiles of H3K4me3, H3K4me1, H3K27me3 and H3K27ac from the livers of mice aged between 3 months and 12 months and fed 30% caloric restriction diet (CR) or standard diet (SD).”

The comparison of different age profiles of histone H3 marks revealed global redistribution of histone H3 modifications with time, in particular in intergenic regions and near transcription start sites, as well as altered correlation between the profiles of different histone modifications. Moreover, feeding mice with caloric restriction diet, a treatment known to retard aging, reduced the extent of changes occurring during the first year of life in these genomic regions.

“In conclusion, while our data do not establish that the observed changes in H3 modification are causally involved in aging, they indicate age, buffered by caloric restriction, releases the histone H3 marking process of transcriptional suppression in gene desert regions of mouse liver genome most of which remain to be functionally understood.”

DOI: https://doi.org/10.18632/aging.204107 

Corresponding Author: Marco Giorgio – marco.giorgio@unipd.it 

Keywords: epigenetics, aging, histones, ChIP-seq, diet

Sign up for free Altmetric alerts about this article:  https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.204107

About Aging-US:

Launched in 2009, Aging (Aging-US) publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Follow Aging on social media: 

  • SoundCloud – https://soundcloud.com/Aging-Us
  • Facebook – https://www.facebook.com/AgingUS/
  • Twitter – https://twitter.com/AgingJrnl
  • Instagram – https://www.instagram.com/agingjrnl/
  • YouTube – https://www.youtube.com/agingus​
  • LinkedIn – https://www.linkedin.com/company/aging/
  • Pinterest – https://www.pinterest.com/AgingUS/

For media inquiries, please contact media@impactjournals.com.

Aging (Aging-US) Journal Office
6666 E. Quaker Str., Suite 1B
Orchard Park, NY 14127
Phone: 1-800-922-0957, option 1

###


Read More

Continue Reading

Government

FDA asks for COVID boosters to fight Omicron’s BA.4, BA.5 subvariants

The U.S. Food and Drug Administration on Thursday recommended booster doses of COVID-19 vaccines be modified beginning this fall to include components…

Published

on

FDA asks for COVID boosters to fight Omicron’s BA.4, BA.5 subvariants

By Michael Erman

June 30 (Reuters) – The U.S. Food and Drug Administration on Thursday recommended booster doses of COVID-19 vaccines be modified beginning this fall to include components tailored to combat the currently dominant Omicron BA.4 and BA.5 subvariants of the coronavirus.

The FDA said manufacturers would not need to change the vaccine for the primary vaccination series, saying the coming year will be “a transitional period when this modified booster vaccine may be introduced.”

FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo

The new booster shots would be bivalent vaccines, meaning doses would target both the original virus as well as the Omicron subvariants.

The decision follows a recommendation by the agency’s outside advisers to change the design of the shots this fall in order to combat more prevalent versions of the coronavirus. read more

BA.4 and BA.5 are now estimated to account for more than 50% of U.S. infections, according the U.S. Centers for Disease Control and Prevention, and have also become dominant elsewhere.

The FDA said in a statement on Thursday that it hoped the modified vaccines could be used in early to mid-fall.

Pfizer Inc (PFE.N) with partner BioNTech SE (22UAy.DE) and Moderna Inc (MRNA.O) have been testing versions of their vaccines modified to combat the BA.1 Omicron variant that caused the massive surge in cases last winter.

Although they have said those vaccines worked against BA.1 and the more recently circulating variants, they did see a lower immune response against BA.4 and BA.5.

The companies had already been manufacturing their BA.1 vaccines, and said on Tuesday that swapping to a BA.4/BA.5 version could slow the rollout.

Pfizer/BioNTech, which on Wednesday announced a $3.2 billion contract to supply more COVID vaccine doses to the United States, said they would have a substantial amount of BA.4/BA.5 vaccine ready for distribution by the first week of October. read more

Moderna said it would be late October or early November before it would have the newly modified vaccine ready.

Reporting by Michael Erman in New Jersey and Leroy Leo in Bengaluru; Editing by Jonathan Oatis and Bill Berkrot

Our Standards: The Thomson Reuters Trust Principles.

Source: Reuters

Read More

Continue Reading

Trending